Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies)

Metabolic Diseases
0
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
2100%

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
exenatideN/APeptide1 trial
Active Trials
NCT01077323Completed363,766Est. Mar 2008
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
exenatideN/APeptide

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Eli Lilly and Companyexenatide

Clinical Trials (1)

Total enrollment: 363,766 patients across 1 trials

A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents

Start: Sep 2004Est. completion: Mar 2008363,766 patients
N/ACompleted

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space